ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

ClinicalTrials.gov ID: NCT07220759

Public ClinicalTrials.gov record NCT07220759. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes

Study identification

NCT ID
NCT07220759
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
330 participants

Conditions and interventions

Interventions

  • Cagrilintide Drug
  • Placebo (matched to Cagrilintide) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 4, 2025
Primary completion
May 11, 2027
Completion
Jun 29, 2027
Last update posted
Apr 20, 2026

2025 – 2027

United States locations

U.S. sites
21
U.S. states
13
U.S. cities
21
Facility City State ZIP Site status
Univ of Alabama_Birmingham Birmingham Alabama 35294
Chambliss Clinical Trials, LLC Montgomery Alabama 36106
Elite Clinical Network - Tucson Tucson Arizona 85704
Scripps Whittier Diabetes Inst La Jolla California 92037
Clinical Trials Research Lincoln California 95648
Pacific Clinical Studies Los Alamitos California 90720
Walgreens - Store 4442 Kissimmee Florida 34746
Optimal Research Sites Orange City Florida 32763
Center for Diab,Obes & Metab Pembroke Pines Florida 33024
Palm Beach Research Center West Palm Beach Florida 33409
East West Med Res Inst Honolulu Hawaii 96814
MediSphere Medical RC Evansville Indiana 47714
Walgreens - Store 3915 Las Vegas Nevada 89146
Chear Center LLC The Bronx New York 10455
Centricity Res New Bern Multispeciality New Bern North Carolina 28562
Accellacare Wilmington North Carolina 28401
Spartanburg Medical Research Spartanburg South Carolina 29303
Holston Medical Group_Bristol Bristol Tennessee 37620
Velocity Clinical Res-Dallas Dallas Texas 75230
TPMG Clinical Research Newport News Virginia 23606
National Clin Res Inc. Richmond Virginia 23294

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07220759, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 20, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07220759 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →